Patent · US Active

Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens

US8383102B2 · kind B2 · utility

8Cited by

0References

15Claims

0Family size

Assignee

The United States of America, as represented by the Secretary of Agriculture · US

Inventor

David M. Donovan · Baltimore, US

Key dates

Filing date	May 21, 2010
Grant date	Feb 26, 2013
Priority date	—
Expiry date	Jun 25, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/03
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Lysostaphin is a bacteriocin secreted by S. simulans to kill S. aureus, and has been shown to also be a potent antimicrobial for many antibiotic-resistant strains of S. aureus. By adding a ˜13 amino acid protein transduction domain (PTD) from the HIV-TAT protein to lysostaphin to form lysostaphin-PTD, both extracellular and intracellular forms of S. aureus and MRSA are killed in all (multiple) cell types examined.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.